Introduction of Olanib 150 Mg
Olanib 150 mg is an advanced oral medication used in the treatment of specific types of cancers, including ovarian, breast, pancreatic, and prostate cancer. It contains the active ingredient Olaparib, a PARP inhibitor (Poly ADP-Ribose Polymerase inhibitor) that targets cancer cells with defective DNA repair mechanisms especially in individuals with BRCA1 or BRCA2 mutations.
Approved by regulatory agencies, including the U.S. Food and Drug Administration (FDA), Olaparib is globally recognized under the brand name Lynparza®. Olanib 150 mg, manufactured by Everest Pharmaceuticals Ltd, offers a cost-effective and therapeutically equivalent alternative to the branded version. It is widely used as a first-line maintenance therapy and as a standalone treatment in advanced or recurrent cancers where traditional chemotherapy is either not effective or not tolerated.
Pharmaceutical Formulation of Olanib 150 Mg
Olanib 150 mg is formulated as an oral film-coated tablet specifically designed for systemic delivery of Olaparib, a targeted PARP inhibitor used in cancer treatment. Each tablet contains 150 mg of Olaparib, the active pharmaceutical ingredient (API), along with a combination of pharmaceutically acceptable excipients to ensure stability, absorption, and consistent therapeutic action.
Key formulation details:
- Dosage Form: Film-coated tablet
- Route of Administration: Oral
- Active Ingredient: Olaparib 150 mg
- Tablet Appearance: Light yellow to beige, oval-shaped, easy-to-swallow tablets
Excipients and Functional Role:
To support the bioavailability and shelf stability of the product, each Olanib tablet includes inactive ingredients such as:
- Lactose Monohydrate – filler for volume and tablet strength
- Microcrystalline Cellulose – enhances tablet integrity
- Hypromellose – used for film coating and controlled release
- Magnesium Stearate – serves as a lubricant
- Sodium Starch Glycolate – aids in tablet disintegration
- Titanium Dioxide and Iron Oxide – used in film coating for appearance and UV protection
Why Pharmaceutical Formulation Matters
The pharmaceutical formulation of Olanib 150 mg tablets ensures:
- Accurate and stable dosing of Olaparib
- Efficient absorption in the gastrointestinal tract
- Patient compliance through easy oral administration
- Extended shelf life and transport durability, especially for online buyers of Olanib
Because Olanib tablets are taken long-term in many cases, consistent quality and formulation precision are essential. The oral dosage form allows patients to receive advanced targeted therapy from the comfort of home, avoiding hospital visits for injectable treatments.
Olanib Indications: What Types of Cancer Does It Treat?
Olanib 150 mg is used to treat several cancers, especially in patients with BRCA mutations:
- Ovarian Cancer – Maintenance treatment after chemotherapy.
- Breast Cancer – For BRCA-mutated, HER2-negative metastatic cases.
- Pancreatic Cancer – For patients with BRCA mutations after platinum chemo.
- Prostate Cancer – For advanced mCRPC with specific gene mutations.
This medication is especially effective in patients with BRCA gene mutations. It may be used as a first-line maintenance treatment or as part of a combination therapy depending on the cancer type and patient condition.
Why Doctors Choose Olanib
- Targeted Action – Specifically blocks PARP in cancer cells with DNA repair issues.
- Proven Results – Clinically effective in extending survival for BRCA-mutated cancers.
- Oral Convenience – Easy-to-take tablets, no hospital visits needed.
- Affordable Option – A cost-effective alternative to branded Olaparib (Lynparza®).
Who Should Use Olanib?
Olanib (Olaparib) is recommended for patients who:
- Patients with BRCA mutations – Especially those with hereditary cancer risks.
- Women with ovarian cancer – After response to platinum-based chemotherapy.
- Patients with metastatic breast cancer – With BRCA-positive, HER2-negative status.
- Pancreatic cancer patients – With confirmed BRCA gene mutations.
- Men with prostate cancer – Especially with mCRPC and HRR gene mutations.
Olanib Dosage & Administration
The standard dose of Olanib 150 mg is usually two tablets taken twice daily (totaling 300 mg per day). However, your doctor may adjust your Olanib dose depending on your health condition, response, or side effects.
Here are general guidelines:
- How to take Olanib: Swallow the tablets whole, with or without food.
- Olanib dosing may vary if you have liver or kidney issues.
- Olanib dose reduction might be necessary if side effects appear.
- Always follow your doctor’s prescription strictly.
Side Effects of Olanib 150 mg
Olanib 150 mg (Olaparib) may cause side effects, like all cancer medications. Most are manageable, but some may need medical attention. Knowing the risks helps in early detection and better treatment outcomes.
Common Side Effects
These often occur during early weeks of using Olanib tablets: These are usually mild and may improve over time or with Olanib dose reduction.
- Fatigue
- Nausea or vomiting
- Anemia (low red blood cells)
- Loss of appetite
- Constipation or diarrhea
- Headache
- Indigestion or stomach pain
- Taste changes
Serious Side Effects
Some rare but serious side effects of Olanib 150 mg include:
- Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
- Pneumonitis (lung inflammation)
- Severe bone marrow suppression
- Changes in kidney or liver function
Seek immediate help if you notice fever, breathing issues, unusual bleeding, or extreme fatigue.
Long-Term Side Effects
Patients on extended Olanib therapy may face:
- Ongoing fatigue
- GI discomfort
- Hair thinning
- Gradual blood count changes
Doctors may adjust Olanib dosing if needed.
Higher Risk Groups
Side effects may be more likely in patients with:
- Liver or kidney disease
- Low blood cell counts
- Combination chemotherapy
Such patients need closer monitoring and possible dose adjustments.
Managing Side Effects
- Take tablets with food to reduce nausea
- Rest and hydrate for fatigue
- Regular blood tests to monitor counts
- Never skip or double doses; consult your doctor for Olanib dose reduction if needed
Though side effects vary, many patients tolerate Olanib (Olaparib) well and see positive treatment results.
Olanib FDA Approval & Regulatory Status
Olanib 150 mg is the generic version of Olaparib, a PARP inhibitor approved by the U.S. FDA for treating multiple cancers. While Olanib itself is not branded, it is based on the FDA-approved active ingredient Olaparib, ensuring similar safety and effectiveness when manufactured by licensed producers like Everest Pharmaceuticals Ltd.
Key FDA Approvals for Olaparib:
- Dec 2014 – Approved for advanced ovarian cancer with BRCA mutations
- Aug 2017 – Approved as maintenance therapy for recurrent ovarian cancers
- Jan 2018 – Approved for BRCA-mutated, HER2-negative breast cancer
- Dec 2019 – Approved for BRCA-positive pancreatic cancer
- May 2020 – Approved for metastatic prostate cancer with HRR gene mutations
These approvals cover the same cancer types that Olanib 150 mg tablets are used for globally.
Is Olanib FDA Approved?
Olanib contains the same molecule, Olaparib, which is FDA approved. It is produced in WHO-GMP certified facilities, ensuring it meets global regulatory standards for quality and safety.
Clinical Benefits of Olanib 150 mg
Olanib 150 mg (Olaparib) offers proven benefits in treating cancers with BRCA mutations and HRD. It is trusted in the treatment of ovarian, breast, pancreatic, and prostate cancers.
Key Benefits:
- Delays Cancer Progression
Clinical trials show Olanib extends progression-free survival in BRCA-positive patients. - Improves Quality of Life
Oral tablets allow at-home treatment with fewer hospital visits and better tolerability. - Targeted Action, Fewer Side Effects
As a PARP inhibitor, it targets cancer cells without harming healthy ones. - Effective Across Multiple Cancers
Approved uses include ovarian, breast, pancreatic, and prostate cancers. - Affordable Alternative
Olanib cost is much lower than branded Olaparib, making treatment more accessible. - Prolongs Progression-Free Survival (PFS)
Clinical trials (such as SOLO-1, SOLO-2, and OlympiAD) have shown that Olaparib significantly delays disease progression in patients with BRCA-mutated cancers. Many patients on Olanib (Olaparib) enjoy longer periods without cancer growth compared to those on standard chemotherapy.
Pregnancy and Lactation
Olanib 150 mg (Olaparib) is not recommended during pregnancy due to the risk of harm to the unborn baby. Women of childbearing potential should use effective contraception during treatment and for at least 6 months after the last dose.
- Pregnancy Warning: May cause fetal harm; avoid use unless absolutely necessary.
- Lactation Warning: Breastfeeding is not advised during treatment and for 1 month after the final dose, as Olaparib may pass into breast milk.
Precautions and Warnings
Before using Olanib 150 mg, consider these important precautions:
- Blood Disorders: Monitor for signs of anemia, low platelets, or white blood cell issues.
- Lung Inflammation: Discontinue if unexplained cough, fever, or breathing problems occur (possible pneumonitis).
- Kidney & Liver Function: Regular testing is needed as Olanib tablets may affect organ function.
- Drug Interactions: Avoid strong CYP3A inhibitors or inducers; they may alter Olanib dosing levels.
- Contraception Needed: Use effective birth control during and after treatment due to risk of fetal harm.
Always follow your doctor’s advice before starting Olanib (Olaparib) to avoid complications.
What to Do in Case of Overdose
If you accidentally take more than the recommended dose of Olanib 150 mg tablets, seek immediate medical help. Overdose symptoms may include severe nausea, vomiting, dizziness, or unusual bleeding. Do not double the dose if you miss one.
What to Do in:
- Do not wait — seek emergency medical help immediately.
- Bring the Olanib tablets or packaging for identification.
- No specific antidote exists; treatment is supportive based on symptoms.
- Monitor vital signs, kidney, liver, and blood function closely.
- Avoid double dosing if a dose is missed — follow your doctor’s advice.
Pharmacological Class and Drug Category
Olanib 150 mg belongs to the pharmacological class of PARP inhibitors (Poly ADP-Ribose Polymerase inhibitors). It is classified as a targeted cancer therapy that works by blocking the PARP enzyme, which cancer cells use to repair damaged DNA.
This drug category is part of oral oncology medicines focused on treating cancers with specific genetic mutations like BRCA1 and BRCA2. By inhibiting PARP, Olanib (Olaparib) causes cancer cell death while sparing healthy cells, making it a precise and effective treatment option.
Manufactured by Everest Pharmaceuticals Ltd: Trusted Quality
Olanib 150 mg tablets are proudly manufactured by Everest Pharmaceuticals Ltd, a leader in high-quality, affordable oncology medicines. Everest Pharma follows strict WHO-GMP and international quality standards to ensure every batch of Olanib (Olaparib) is safe, effective, and consistent.
Their advanced manufacturing processes include rigorous quality control, precise formulation, and modern technology to deliver medicines that meet global regulatory requirements. Everest Pharmaceuticals’ commitment to innovation and patient safety has earned the trust of healthcare professionals and patients worldwide.
Choosing Olanib from Everest Pharma means getting a reliable, FDA-approved generic equivalent at an affordable price, with guaranteed quality you can depend on.
Olanib Price and Online Buying Guide
At Unit Pharmacy, Olanib 150 Mg (Olaparib) is available for $410 USD per box. We ensure authenticity, affordability, and global shipping for patients seeking quality cancer care.
Current Price:
- $410 USD per box (Everest Pharmaceuticals Ltd.)
- Includes pharmacist support and verified product details.
How to Buy Online:
- Visit unitpharmacy.com
- Add to cart → Checkout
- Choose shipping and payment options
- Prescription verified → Order shipped globally
Why Choose Us:
- 100% genuine Olaparib
- Affordable Olaparib alternative
- Trusted by patients worldwide
- Safe, fast, and discreet delivery
Whether you are searching for “buy olaparib online”, “olaparib near me”, or affordable olaparib prices, Unit Pharmacy delivers quality with care.
Olanib Other Names and Alternatives
Olanib 150 mg is the generic version of Olaparib, widely known by its original brand name Lynparza®. In different markets, Olaparib may be sold under various brand names or generics, but they all contain the same active ingredient.
Common Other Names for Olanib:
- Olaparib (generic name)
- Lynparza® (original branded medication)
- Olanib (Olaparib) tablets
Alternatives to Olanib:
For patients seeking options, other PARP inhibitors and related treatments include:
- Niraparib (brand name: Zejula)
- Olaparix (brand name: Beacon)
- Talazoparib (brand name: Talzenna)
Each alternative works similarly by targeting the PARP enzyme but may differ in dosing, side effects, and FDA-approved indications.
Choosing Olanib or Its Alternatives
Doctors often recommend Olanib 150 mg due to its proven efficacy, affordability, and availability as a trusted generic. When considering alternatives, patients should consult their healthcare provider to select the best therapy based on their cancer type, genetic profile, and treatment history.
Supplier: Unit Pharmacy
Unit Pharmacy is a trusted online supplier of genuine Olanib 150 mg (Olaparib) tablets. We provide affordable, high-quality oncology medicines sourced from top manufacturers like Everest Pharmaceuticals Ltd.
Olanib 150 mg works by blocking the PARP enzyme, stopping cancer cells from repairing their DNA, which helps slow cancer growth. Patients worldwide trust Unit Pharmacy for:
- Authentic medicines
- Competitive Olanib price
- Easy online ordering
- Fast, discreet global delivery
Why Buy Olaparix from Unit Pharmacy?
Unit Pharmacy is a trusted supplier of oncology medicines globally. We offer:
- 100% genuine Olaparib guaranteed.
- Transparent pricing: $410 USD per box.
- Easy and secure online ordering.
- Fast, worldwide shipping.
- Expert pharmacist support.
Storage Instructions
Store Olanib 150 mg tablets in a cool, dry place away from sunlight, between 20°C–25°C (68°F–77°F). Keep out of reach of children and in its original packaging until use.
Conclusion: Is Olanib 150 Mg Right for You?
Olanib 150 mg is a powerful, FDA-approved, and affordable cancer treatment option for patients needing Olaparib therapy. With easy online buying options, high manufacturing standards, and global delivery from Unit Pharmacy, patients now have access to the care they deserve.
Whether you’re looking for Olaparib near me, Olanib 150 mg price, or a reliable place to buy Olanib online, Unit Pharmacy is here to support you on your treatment journey.
- Buy Now Unit Pharmacy.
Reviews
There are no reviews yet.